| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 26,271,650 | 44,273,319 | 36,567,420 | 24,351,377 |
| Short-term investments | 11,409,607 | 14,239,145 | 14,235,770 | 23,198,083 |
| Accounts receivable from affiliated entity | - | - | 978,590 | 840,312 |
| Prepaid expenses and other current assets, including from affiliated entity | 1,758,348 | 2,610,882 | 3,398,534 | 4,307,377 |
| Total current assets | 39,439,605 | 61,123,346 | 55,180,314 | 52,697,149 |
| Fixed assets, net | 2,210,759 | 2,527,603 | 2,740,356 | 3,089,293 |
| Investments in affiliated entity | 0 | 2,103,688 | 2,495,730 | 3,085,348 |
| Operating lease right-of-use assets | 6,114,303 | 6,542,923 | 6,956,780 | 7,356,238 |
| Other assets | 2,012,475 | 2,012,475 | 2,012,476 | 2,012,476 |
| Total assets | 49,777,142 | 74,310,035 | 69,385,656 | 68,240,504 |
| Accounts payable and accrued expenses-Nonrelated Party | 9,267,415 | 11,053,618 | 15,323,520 | 15,750,691 |
| Accounts payable and accrued expenses-Related Party | 0 | 74,473 | 379,721 | 369,370 |
| Accrued clinical trial expenses | 817,331 | 650,680 | 955,970 | 1,510,984 |
| Common stock warrant liabilities | 24,929,459 | 29,067,162 | 50,384,043 | 11,420,326 |
| Operating lease liability | 2,908,820 | 2,822,622 | 2,738,490 | 2,656,239 |
| Grant funding liability from affiliated entity | - | - | 42,152 | - |
| Total current liabilities | 37,923,025 | 43,668,555 | 69,823,896 | 31,707,610 |
| Operating lease liability, net of current portion | 5,786,235 | 6,545,204 | 7,281,737 | 8,001,989 |
| Total liabilities | 43,709,260 | 50,213,759 | 77,105,633 | 39,709,599 |
| Preferred stock | 0 | - | 0 | 0 |
| Common stock | 69,773 | 68,997 | 53,572 | 36,719 |
| Additional paid-in capital | 1,841,482,163 | 1,839,830,405 | 1,811,803,850 | 1,802,589,299 |
| Accumulated deficit | -1,834,847,961 | -1,815,165,163 | -1,818,930,043 | -1,773,433,371 |
| Accumulated other comprehensive loss | -636,093 | -637,963 | -647,356 | -661,742 |
| Total inovio pharmaceuticals, inc. stockholders equity | 6,067,882 | 24,096,276 | -7,719,977 | 28,530,905 |
| Total liabilities and stockholders equity | 49,777,142 | 74,310,035 | 69,385,656 | 68,240,504 |
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)